RESUMO
Introdução: A colonoscopia é considerada o exame padrão ouro para diagnóstico do câncer de intestino. Porém o sucesso do exame depende do preparo colônico eficaz. Objetivo: Avaliar a eficácia do picossulfato de sódio (PS) comparativamente ao manitol (MN) no preparo intestinal precedente ao exame de colonoscopia. Material e Métodos: Revisão sistemática de ensaios clínicos randomizados controlados (ECRs). A busca por evidências na literatura científica foi conduzida nas bases de dados PubMed, Embase, Cochrane Library e Biblioteca Virtual da Saúde por meio da combinação dos seguintes indexadores e operadores booleanos: "colonoscopy" AND "picosulfate sodium" AND "mannitol". O risco de viés foi avaliado pela ferramenta RoB 2.0. Resultados: O efeito do PS sobre a limpeza colônica foi similar ou até mesmo inferior àquele demonstrado pelo MN. Entretanto, observou-se maior tolerabilidade e palatabilidade e menor frequência de efeitos colaterais associados ao PS em comparação ao MN. Ressalta-se a carência de rigor metodológico dos estudos incluídos, visto que 33% destes foram classificados com "alto risco" de viés, enquanto 66,7% apresentaram "alguma preocupação". Conclusão: Em comparação ao MN, o uso de PS não promove uma maior qualidade de limpeza colônica, embora esteja relacionado à menor ocorrência de efeitos colaterais, maior tolerabilidade e palatabilidade. Assim, sugere-se que a inclusão do PS seja considerada apenas em pacientes com intolerância importante ou surgimento de efeitos adversos que inviabilizem o preparo com MN.
Introduction: Colonoscopy is considered the gold standard test for diagnosing bowel cancer. The success of the exam, however, depends on effective colonic preparation. Objective: To evaluate the effectiveness of Sodium Picosulfate (PS) compared to Mannitol (MN) in intestinal preparation before colonoscopy examination. Material and Methods: Systematic review of randomized controlled clinical trials (RCTs). The search for evidence in the scientific literature was conducted in the PubMed, Embase, Cochrane Library and Virtual Health Library databases by combining the following indexers and Boolean operators: "colonoscopy" AND "picosulfate sodium" AND "Mannitol". The risk of bias was assessed using the RoB 2.0 tool. Results: The effect of PS on colonic cleansing was similar or even lower than that demonstrated by MN. However, greater tolerability and palatability and a lower frequency of side effects associated with PS were observed compared to MN. The lack of methodological rigor of the included studies is highlighted, as 33% of these were classified as "high risk" of bias, while 66.7% presented "some concern". Conclusion: Compared to MN, the use of PS does not promote a higher quality of colon cleansing, although it is related to the lower occurrence of side effects, greater tolerability and palatability. Therefore, it is suggested that the inclusion of PS must be considered only in patients with significant intolerance or the emergence of adverse effects that make preparation with MN unfeasible.
Assuntos
Picolinas , Colonoscopia , Exames Médicos , Neoplasias Intestinais , NeoplasiasRESUMO
Over the past few decades, several publications have investigated the role of Epstein-Barr virus (EBV) in head and neck squamous cell carcinomas, and an increasing number of them have shown its presence in laryngeal tumors. The purpose of this meta-analysis was to evaluate the association of EBV with laryngeal carcinoma. The search was carried out in two databases, Scopus and PubMed, using the following terms: "Epstein-Barr virus" and "laryngeal carcinoma". A total of 187 records were found, of which 31 were selected for meeting the inclusion and exclusion criteria. The meta-analysis yielded an overall pooled prevalence of 43.72% (95% confidence interval (CI): 34.35-53.08). Studies carried out in Europe and Eurasia had slightly higher pooled prevalence than other subgroups, while the prevalence of studies performed in developed countries was higher than in developing countries (46.37% vs. 34.02%). Furthermore, laryngeal carcinoma occurred almost three times as often among EBV-infected individuals compared to those without EBV infection (odds ratio = 2.86 (95% CI: 1.18-6.90); Begg's test, p = 0.843 and Egger's test, p = 0.866). Our findings support the idea that EBV is related to laryngeal carcinoma. However, further studies are needed before recognizing a definitive etiological role of EBV in the development and/or progression of laryngeal carcinomas.
RESUMO
Despite the recent announcement of the new pathogenic coronavirus to man, SARS-CoV2, a large number of publications are presented to the scientific community. An organized and systematic review of the epidemiological, etiological, and pathogenic factors of COVID-19 is presented. This is a systematic review using the databases MEDLINE, EMBASE, Web of Science, SCIELO; the descriptors coronavirus, SARS-CoV-2, etiology, epidemiology, pathophysiology, pathogenesis, COVID-19, with publications from December 2019 to January 2021, resulting in more than 800 publications and 210 selected. The data suggest that COVID-19 is associated with SAR-CoV-2 infection, with the transmission of contagion by fomites, salivary droplets, and other forms, such as vertical and fecal-oral. The bat and other vertebrates appear to be reservoirs and part of the transmission chain. The virus uses cell receptors to infect human cells, especially ACE2, like other coronaviruses. Heat shock proteins have different roles in the infection, sometimes facilitating it, sometimes participating in more severe conditions, when not serving as a therapeutic target. The available data allow us to conclude that COVID-19 is a pandemic viral disease, behaving as a challenge for public health worldwide, determining aggressive conditions with a high mortality rate in patients with risk factors, without treatment, but with the recent availability of the first vaccines.
Assuntos
COVID-19 , Animais , Humanos , Masculino , Pandemias , RNA Viral , SARS-CoV-2RESUMO
Tamoxifen efficacy in breast cancer is suspected to depend on adherence and intact drug metabolism. We evaluated the role of adherence behavior and pharmacogenetics on the formation rate of (Z)-endoxifen. In 192 Brazilian patients, we assessed plasma levels of tamoxifen and its metabolites at 3, 6, and 12 months of treatment (liquid-chromatography tandem mass spectrometry), adherence behavior (Morisky, Green, and Levine medication adherence scale), and cytochrome P450 2D6 (CYP2D6) and other pharmacogene polymorphisms (matrix-assisted laser-desorption-ionization time of flight) mass spectrometry, real-time polymerase chain reaction). Adherence explained 47% of the variability of tamoxifen plasma concentrations (P < 0.001). Although CYP2D6 alone explained 26.4%, the combination with adherence explained 40% of (Z)-endoxifen variability at 12 months (P < 0.001). The influence of low adherence to not achieving relevant (Z)-endoxifen levels was highest in patients with noncompromised CYP2D6 function (relative risk 3.65; 95% confidence interval 1.48-8.99). As a proof-of-concept, we demonstrated that (Z)-endoxifen levels are influenced both by patient adherence to tamoxifen and CYP2D6, which is particularly relevant for patients with full CYP2D6 function.
Assuntos
Antineoplásicos Hormonais/uso terapêutico , Neoplasias da Mama/tratamento farmacológico , Citocromo P-450 CYP2D6/genética , Adesão à Medicação/estatística & dados numéricos , Tamoxifeno/uso terapêutico , Adulto , Idoso , Idoso de 80 Anos ou mais , Antineoplásicos Hormonais/farmacocinética , Brasil , Neoplasias da Mama/sangue , Neoplasias da Mama/genética , Citocromo P-450 CYP2D6/metabolismo , Monitoramento de Medicamentos/estatística & dados numéricos , Feminino , Humanos , Pessoa de Meia-Idade , Testes Farmacogenômicos/estatística & dados numéricos , Variantes Farmacogenômicos , Autorrelato/estatística & dados numéricos , Tamoxifeno/análogos & derivados , Tamoxifeno/sangue , Tamoxifeno/metabolismo , Tamoxifeno/farmacocinética , Adulto JovemRESUMO
The purpose of this meta-analysis is to evaluate the association of Epstein-Barr virus (EBV) with oral squamous cell carcinoma (OSCC). We searched the electronic scientific databases of PubMed and Scopus and included a total of 53 studies that were published from 1990 to 2019. The analysis yielded a 45.37% (95% confidence interval [CI]: 38.90-51.84; p < 0.001) overall pooled prevalence of EBV. Studies that used the applied methods of in situ hybridization, polymerase chain reaction, immunology, or RNA microarray showed the following pooled prevalence: 46.08%, 40.32, 54.97%, and 74.89%, respectively. EBV-infected individuals have a 2.5 higher risk for developing OSCC (odds ratio: 2.57; 95% CI: 1.23% to 5.36%; p < 0.001). The present meta-analysis supports the hypothesis of EBV association with OSCC, pointing to this virus as a risk factor for neoplasia. Our findings also suggest that EBV latent transcripts (latent membrane protein 1, EBV nuclear antigen 1 and 2, and EBV-encoded small RNAs) have an important role in this process. Furthermore, novel advancements could arise from large and standardized studies that are constructed to probe for other latent gene expression, eliminate confounding factors (tobacco, alcohol, and high-risk human papillomavirus infection), and define the relationship between EBV and oral carcinomas.
Assuntos
Carcinoma de Células Escamosas/fisiopatologia , Infecções por Vírus Epstein-Barr/fisiopatologia , Herpesvirus Humano 4/fisiologia , Neoplasias Bucais/fisiopatologia , Consumo de Bebidas Alcoólicas/efeitos adversos , Consumo de Bebidas Alcoólicas/epidemiologia , Consumo de Bebidas Alcoólicas/fisiopatologia , Carcinoma de Células Escamosas/epidemiologia , Carcinoma de Células Escamosas/virologia , Infecções por Vírus Epstein-Barr/epidemiologia , Humanos , Neoplasias Bucais/epidemiologia , Neoplasias Bucais/virologia , Fumar/efeitos adversos , Fumar/epidemiologia , Fumar/fisiopatologiaRESUMO
INTRODUCTION: End-stage renal disease (ESRD) is a public health problem and, in Brazil, lacks of data on one of the main treatments, hemodialysis, are still identified. OBJECTIVE: To determine, through description of resources used in ESRD treatment and its complications, the cost associated to hemodialysis and supplementary medical therapy in patients attended by Brazilian Public Health (SUS). METHODS: Methods of cross-sectional and prospective cohort observational analysis were conducted using public data, where information about inpatient and outpatient resource use and patients' characteristics were collected. From described resource use, costs were calculated. In cross-sectional analysis subjects who underwent hemodialysis between January/2008 and November/2012 were considered and in prospective cohort, started in 2009. Descriptive analyses were performed. RESULTS: 91,475 and 118,847 hemodialysis procedures were performed in 2008 and 2012, respectively, and 24.8% of increase was estimated until 2017. Analysis by federation unit showed that São Paulo, Minas Gerais and Rio de Janeiro states represented almost half of the procedures observed, with mean cost per patient of US$ 7,932.52 in 2008 and US$ 9,112.75 in 2011. In the cohort, composed by 96,600 subjects, the most used drug was alfaepoetin and 8% of the sample used calcitriol 1.0 mcg. The occurrence of complications was observed in 28.2% of patients. CONCLUSION: After data analysis, different aspects of hemodialysis use were demonstrated, with an increase in amount of procedures and, also, in disease related expenses.
Assuntos
Falência Renal Crônica/economia , Falência Renal Crônica/terapia , Diálise Renal/economia , Adulto , Idoso , Brasil , Estudos Transversais , Atenção à Saúde , Feminino , Custos de Cuidados de Saúde , Humanos , Masculino , Pessoa de Meia-Idade , Estudos ProspectivosRESUMO
ResumoIntrodução:A doença renal crônica (DRC) é um problema de saúde pública e, no Brasil, ainda são identificadas carências de dados sobre características de um dos principais tratamentos, a hemodiálise.Objetivo:Determinar, por meio da descrição do consumo de recursos para o tratamento e suas complicações, o custo associado à hemodiálise e às terapias medicamentosas suplementares em pacientes financiados pelo SUS.Métodos:Métodos de análise observacional transversal e coorte prospectiva foram utilizados considerando dados públicos, dos quais foram coletadas informações referentes a procedimentos hospitalares e ambulatoriais, além de características dos pacientes. Os custos foram calculados a partir dos recursos descritos. Na análise transversal foram considerados indivíduos que realizaram hemodiálise entre janeiro de 2008 e novembro de 2012 e na coorte prospectiva, iniciada em 2009. Análises descritivas foram conduzidas.Resultados:Um total de 91.475 e 118.847 procedimentos de hemodiálise foram realizados em 2008 e 2012, respectivamente, e, para o ano 2017, foi estimado um aumento de 24,8%. A análise por unidade federativa mostrou que São Paulo, Minas Gerais e Rio de Janeiro representam quase metade dos procedimentos, com média de custo, por paciente, de US$ 7.932,52 em 2008, e de US$ 9.112,75 em 2011. Na coorte, composta por 96.600 indivíduos, o medicamento mais utilizado foi a alfapoetina, além de 8% da amostra utilizar calcitriol 1,0 mcg. Foi observada a ocorrência de complicações em 28,2% dos pacientes.Conclusão:Após análise dos dados, diferentes aspectos da utilização da hemodiálise foram demonstrados, sendo observado um aumento na quantidade de procedimentos e, também, nos gastos decorrentes do procedimento.
AbstractIntroduction:End-stage renal disease (ESRD) is a public health problem and, in Brazil, lacks of data on one of the main treatments, hemodialysis, are still identified.Objective:To determine, through description of resources used in ESRD treatment and its complications, the cost associated to hemodialysis and supplementary medical therapy in patients attended by Brazilian Public Health (SUS).Methods:Methods of cross-sectional and prospective cohort observational analysis were conducted using public data, where information about inpatient and outpatient resource use and patients' characteristics were collected. From described resource use, costs were calculated. In cross-sectional analysis subjects who underwent hemodialysis between January/2008 and November/2012 were considered and in prospective cohort, started in 2009. Descriptive analyses were performed.Results:91,475 and 118,847 hemodialysis procedures were performed in 2008 and 2012, respectively, and 24.8% of increase was estimated until 2017. Analysis by federation unit showed that São Paulo, Minas Gerais and Rio de Janeiro states represented almost half of the procedures observed, with mean cost per patient of US$ 7,932.52 in 2008 and US$ 9,112.75 in 2011. In the cohort, composed by 96,600 subjects, the most used drug was alfaepoetin and 8% of the sample used calcitriol 1.0 mcg. The occurrence of complications was observed in 28.2% of patients.Conclusion:After data analysis, different aspects of hemodialysis use were demonstrated, with an increase in amount of procedures and, also, in disease related expenses.
Assuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Idoso , Diálise Renal/economia , Falência Renal Crônica/economia , Falência Renal Crônica/terapia , Brasil , Estudos Transversais , Estudos Prospectivos , Custos de Cuidados de Saúde , Atenção à SaúdeRESUMO
BACKGROUND: Genetic factors may encourage or even cause the occurrence of mood disorders such as anxiety and/or depression. However, despite the significant amount of work and sophisticated technology is not fully elucidated which genes or regions of nuclear or mitochondrial DNA, or which types of genetic changes, alone or in combination, can represent reliable genetic markers of anxiety and/or depression. OBJECTIVE: To identify whether there are genetic changes that can cause depression or anxiety and if there are genetic markers that can be used to detect these changes. METHODS: A systematic review of 01.01.2004 to 03.28.2014 was held by VHL (Virtual Health Library). The search was performed with the descriptors ׳׳anxiety׳׳, ׳׳depression׳׳, "mutation" and "genetic markers׳׳. The selected articles were indexed in MEDLINE. The information pertinent to the study was selected, categorized and analyzed. Of the 374 articles found, 29 met the eligibility criteria. RESULTS: FMR1 gene polymorphisms, dopaminergic (DAT, DRD, COMT), serotonin (5-HTTLPR, HTR1A, HTR2A), interleukins, MCR1, HCN (potassium channel), neurorregulinas, GABAergic (GABA, GAD, DBI) DBI, GABA (Gabra) receptors and GAD genes (GAD1, GAD2) appear to contribute to generate condition of depression or anxiety like. Mutations in mitochondrial DNA in 124pb allele of D2S2944 in ofil 1 and 2 loci of chromosomes 4 and 7, respectively, and the chromosomes 8p, 17p and 15q appear to be associated with the origin of depression or anxiety. CONCLUSION: Some studies show only associations with one of the disorders, mainly anxiety. Few have shown association with both simultaneously. Other studies showed specific association of gender, or even specific ethnic groups. It was noticed, controversies over certain markers. Interesting results were observed in combination of changes, especially in cases of SNPs, indicating that perhaps this is the most appropriate way to find reliable markers.
Assuntos
Transtornos de Ansiedade/genética , Ansiedade/genética , Depressão/genética , Transtorno Depressivo/genética , Marcadores Genéticos , Predisposição Genética para Doença , Alelos , Humanos , Mutação , Polimorfismo Genético , Polimorfismo de Nucleotídeo ÚnicoRESUMO
INTRODUÇÃO: A Insuficiência Renal Crônica (IRC) tem incidência alarmante neste século. A diálise peritoneal, uma das modalidades de terapia renal pode ter complicações, e entre estas a fibrose peritoneal, que ocorre com o decorrer dos anos nestes pacientes. Sua forma mais grave é a chamada peritonite esclerosante encapsulante, levando à mudança de terapia dialítica. OBJETIVO: Estudar a influência do uso do captopril na fibrose peritoneal induzida em ratos pelo uso de solução de glicose a 4,25 %. MÉTODOS: Estudo prospectivo controlado, em ratos Wistar não urêmicos. Foram estudados 20 animais. Os animais foram submetidos diariamente à punção abdominal, sendo infundida solução de diálise peritoneal com glicose a 4,25% na dose de 10 ml/100 g de peso. Os animais foram divididos em 2 grupos: experimental e controle. O grupo experimental recebeu captopril na dose de 30 mg/kg/dia por gavagem. O grupo controle não recebeu nenhuma droga. Foram acompanhados por 21 e 49 dias. Ao final do período foram submetidos à procedimento cirúrgico para retirada de peritônio parietal e visceral. As amostras obtidas foram analisadas histologicamente, usando-se coloração Hematoxilina - Eosina e Sirius Red, para avaliação do grau de fibrose. RESULTADOS: A análise mostrou que a intensidade da fibrose, a espessura do peritônio e o número de células não atingiram diferença estatisticamente significante entre os grupos experimental e controle. CONCLUSÃO: O estudo mostrou que o uso do captopril não foi capaz de alterar a intensidade da fibrose peritoneal induzida pelo uso de solução de diálise em ratos.
INTRODUCTION: Chronic renal failure has alarming incidence all over the world in this century. Among the modalities of dialytic treatment, peritoneal dialysis has a major spot. This method of dialytictreatment may present complications, and among those is peritoneal fibrosis. It occurs in patients submitted to peritoneal dialysis along years. It's most dangerous form is sclerosing encapsulant peritonitis, wich leads to a need of change in modality and many times lead to death. OBJECTIVE: Study the influence of using captopril on the peritoneal fibrosis induced in rats using solution with glucoses 4.25%. METHODS: Prospective controlled study in 20 non-uremic Wistar rats. The animals received a peritoneal infusion of 10 ml/100g of peritoneal dialysis solution glucose 4.25% on a daily basis. The animals were divided in two groups: experimental and control. The experimental group received captopril 30 mg/kg/d, by a gastric tube. The control group did not receive any drug. The follow-up was 21 and 49 days. At the end, one surgical procedure was performed to get histological samples of visceral and parietal peritoneum. The samples were analyzed using Hematoxylin Eosin and Sirius Red, to evaluate the severity of the fibrosis. RESULTS: The analysis showed that the intensity of the fibrosis, the peritoneal thickness and the cell number in experimental and control groups were not statistically significant different in experimental and control groups. CONCLUSION: Our findings indicate that captopril do not decrease the intensity of fibrosis on the peritoneal membrane that happens on rats on peritoneal dialysis.
Assuntos
Animais , Masculino , Ratos , Inibidores da Enzima Conversora de Angiotensina/uso terapêutico , Captopril/uso terapêutico , Glucose/administração & dosagem , Diálise Peritoneal , Fibrose Peritoneal/prevenção & controle , Fibrose Peritoneal/induzido quimicamente , Ratos WistarRESUMO
INTRODUCTION: Chronic renal failure has alarming incidence all over the world in this century. Among the modalities of dialytic treatment, peritoneal dialysis has a major spot. This method of dialytic treatment may present complications, and among those is peritoneal fibrosis. It occurs in patients submitted to peritoneal dialysis along years. It's most dangerous form is sclerosing encapsulant peritonitis, wich leads to a need of change in modality and many times lead to death. OBJECTIVE: Study the influence of using captopril on the peritoneal fibrosis induced in rats using solution with glucoses 4.25%. METHODS: Prospective controlled study in 20 non-uremic Wistar rats. The animals received a peritoneal infusion of 10 ml/100g of peritoneal dialysis solution glucose 4.25% on a daily basis. The animals were divided in two groups: experimental and control. The experimental group received captopril 30 mg/kg/d, by a gastric tube. The control group did not receive any drug. The follow-up was 21 and 49 days. At the end, one surgical procedure was performed to get histological samples of visceral and parietal peritoneum. The samples were analyzed using Hematoxylin Eosin and Sirius Red, to evaluate the severity of the fibrosis. RESULTS: The analysis showed that the intensity of the fibrosis, the peritoneal thickness and the cell number in experimental and control groups were not statistically significant different in experimental and control groups. CONCLUSION: Our findings indicate that captopril do not decrease the intensity of fibrosis on the peritoneal membrane that happens on rats on peritoneal dialysis.